当前位置:首页 - 行情中心 - 华兰生物(002007) - 财务分析 - 现金流量表

华兰生物

(002007)

  

流通市值:197.16亿  总市值:228.76亿
流通股本:15.74亿   总股本:18.26亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金3,126,050,999.572,147,276,910.29819,616,146.734,451,476,719.5
  收到的税费返还49,102,724.7543,615,704.1339,179,943.62,333,182.08
  收到其他与经营活动有关的现金39,852,562.6731,747,435.6624,077,141.7963,444,684.53
  经营活动现金流入小计3,215,006,286.992,222,640,050.08882,873,232.124,517,254,586.11
  购买商品、接受劳务支付的现金1,472,039,040.29992,572,229.54475,978,555.51,623,341,704.86
  支付给职工以及为职工支付的现金403,650,397.59277,728,469.67152,873,951.85498,704,992.81
  支付的各项税费361,722,030.56252,519,565.37135,377,471.06398,199,167.11
  支付其他与经营活动有关的现金604,942,315.72357,093,959.02125,032,833.141,119,052,221.08
  经营活动现金流出小计2,842,353,784.161,879,914,223.6889,262,811.553,639,298,085.86
  经营活动产生的现金流量净额372,652,502.83342,725,826.48-6,389,579.43877,956,500.25
二、投资活动产生的现金流量:
  收回投资收到的现金9,449,883,910.995,797,844,776.272,601,724,646.2912,224,906,537.78
  取得投资收益收到的现金117,237,144.8990,132,898.3376,856,763.87264,014,024.63
  处置固定资产、无形资产和其他长期资产收回的现金净额1,227,189.05291,070.8569,782.622,685,413.56
  处置子公司及其他营业单位收到的现金净额1,574,940.11,574,940.1--
  投资活动现金流入小计9,569,923,185.035,889,843,685.552,678,651,192.7812,491,605,975.97
  购建固定资产、无形资产和其他长期资产支付的现金132,388,440.3779,212,547.7551,713,943.75197,305,265.37
  投资支付的现金8,581,550,0005,006,000,0002,063,000,00011,760,017,908.4
  投资活动现金流出小计8,713,938,440.375,085,212,547.752,114,713,943.7511,957,323,173.77
  投资活动产生的现金流量净额855,984,744.66804,631,137.8563,937,249.03534,282,802.2
三、筹资活动产生的现金流量:
  取得借款收到的现金987,357,707.08389,103,542.67-724,942,840.01
  筹资活动现金流入平衡项目00-0
  筹资活动现金流入小计987,357,707.08389,103,542.67-724,942,840.01
  偿还债务支付的现金837,000,000447,000,000447,000,0001,179,380,000
  分配股利、利润或偿付利息支付的现金1,058,921,444.1894,947,519.9-1,528,602,067.26
  其中:子公司支付给少数股东的股利、利润152,000,026.4108,800,026.4-167,120,026.4
  支付其他与筹资活动有关的现金17,462,575.217,462,575.2-14,023,913.4
  筹资活动现金流出小计1,913,384,019.31,359,410,095.1447,000,0002,722,005,980.66
  筹资活动产生的现金流量净额-926,026,312.22-970,306,552.43-447,000,000-1,997,063,140.65
四、汇率变动对现金及现金等价物的影响-220,655.21-142,225.98-80,561.38140,062.36
五、现金及现金等价物净增加额302,390,280.06176,908,185.87110,467,108.22-584,683,775.84
  加:期初现金及现金等价物余额773,576,445.84773,576,445.84773,576,445.841,358,260,221.68
  期末现金及现金等价物余额1,075,966,725.9950,484,631.71884,043,554.06773,576,445.84
补充资料:
  净利润-395,191,400.94-999,992,847.58
  资产减值准备--12,739,217.1-58,207,765.52
  固定资产和投资性房地产折旧-130,600,499.11-262,512,275.03
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-130,600,499.11-262,512,275.03
  无形资产摊销-6,627,441.02-12,439,838.81
  长期待摊费用摊销-3,065,974.29-6,026,473.54
  处置固定资产、无形资产和其他长期资产的损失-696,138.29--2,891,234.85
  固定资产报废损失-3,595,906.88-3,527,237.33
  公允价值变动损失--10,582,063.21--15,171,586.8
  财务费用-199,964.52-10,000,229.83
  投资损失--98,522,641.29--62,497,631.37
  递延所得税-19,759,878.06-6,457,511.49
  其中:递延所得税资产减少--6,014,904.38-38,487,550.47
    递延所得税负债增加-25,774,782.44--32,030,038.98
  存货的减少--419,107,984.56--317,321,310.24
  经营性应收项目的减少-253,219,825.18--423,098,940.65
  经营性应付项目的增加-109,756,150.44-333,297,801.22
  其他--325.82--27,966,491.88
  现金的期末余额-950,484,631.71-773,576,445.84
  减:现金的期初余额-773,576,445.84-1,358,260,221.68
  现金及现金等价物的净增加额-176,908,185.87--584,683,775.84
公告日期2026-10-282026-08-292026-04-272026-03-28
审计意见(境内)标准无保留意见
TOP↑